A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia
MK-0457, developed by Merck Sharp & Dohme LLC, targets specific molecular pathways involved in leukemia, particularly those associated with Aurora kinases and BCR-ABL mutations. The asset is positioned within a competitive landscape that includes other targeted therapies for relapsed/refractory leukemia. Given the high unmet medical need in this patient population, successful outcomes could lead to significant market opportunities. The completion of this trial may enhance Merck's portfolio in hematological malignancies, potentially impacting market share against existing therapies. Diligence should focus on the safety profile and efficacy data to assess market entry strategies and potential partnerships.
Indication: Chronic Myelogenous Leukemia in Blast Crisis
Modality: small molecule
Target: Aurora kinase and BCR-ABL
Sponsor: Merck Sharp & Dohme LLC
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Aurora kinase and BCR-ABL
View original source fields
Condition raw: Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute, Myelodysplastic Syndromes, Myelogenous Leukemia, Chronic
Condition normalized: Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute, Myelodysplastic Syndromes, Myelogenous Leukemia, Chronic
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Aurora kinase and BCR-ABL
Target normalized: Aurora kinase and BCR-ABL